drugset / Trial / NCT00531596

Evaluation of Adhesion and Dermal Tolerability of EMSAM

NCT00531596

Phase 4 Completed 300 enrolled Somerset Pharmaceuticals
RandomizedSingle-groupOpen-label

Summary

Examine adhesive and dermal tolerability of EMSAm 6mg/24hr and 12mg/24hr in healthy elderly and non-elderly subjects.

Timeline

Start
2007-04
Primary completion
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Selegiline Unknown 6 mg Other
Comparator Selegiline Unknown 9 mg Other
Comparator Selegiline Unknown 12 mg Other

Indications

No indication recorded.